Group 1 - On December 19, China International Capital Corporation (CICC) experienced a decline of 0.72% with a trading volume of 2.103 billion yuan, while the net financing purchase amounted to 216 million yuan [1] - As of December 19, the total margin balance for CICC reached 2.934 billion yuan, with the financing balance accounting for 2.79% of the circulating market value, indicating a high level compared to the past year [1] - CICC's short selling data on December 19 showed a repayment of 39,600 shares and a sale of 2,100 shares, with the short selling amount calculated at 75,400 yuan, also reflecting a high level compared to the past year [1] Group 2 - CICC, established on July 31, 1995, and listed on November 2, 2020, operates in investment banking, equity sales and trading, fixed income, commodities, currency, wealth management, and investment management [2] - The revenue composition of CICC includes wealth management at 32.58%, equity business at 25.78%, fixed income at 13.38%, investment banking at 11.26%, other at 8.87%, asset management at 4.21%, and private equity at 3.91% [2] Group 3 - As of September 30, CICC had 118,900 shareholders, a decrease of 4.10%, while the average circulating shares per person increased by 4.28% to 24,662 shares [3] - For the period from January to September 2025, CICC reported a revenue of 20.761 billion yuan, representing a year-on-year growth of 54.36%, and a net profit attributable to shareholders of 6.567 billion yuan, with a year-on-year increase of 129.75% [3] Group 4 - CICC has distributed a total of 5.358 billion yuan in dividends since its A-share listing, with 3.041 billion yuan distributed in the last three years [4] - As of September 30, 2025, the top ten circulating shareholders of CICC included Hong Kong Central Clearing Limited as the third-largest shareholder with 123 million shares, an increase of 51.425 million shares from the previous period [4]

Core Viewpoint - Zai Jian Pharmaceutical has submitted an application for listing on the Hong Kong Stock Exchange, with CICC as its sole sponsor, highlighting its focus on innovative therapies in oncology, autoimmune diseases, and hematology [1] Company Overview - Zai Jian Pharmaceutical is a comprehensive biopharmaceutical company dedicated to the discovery, research and development, and commercialization of innovative small molecules and biologics [1] - The company has a product portfolio that includes marketed drugs, late-stage clinical candidates, and early-stage discovery projects [1] Product Pipeline - Zai Jian Pharmaceutical currently has three marketed drugs: - Zepsu (Zepub) is the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China [1] - Zeppin (Zepping) is the first domestically developed innovative JAK inhibitor for the treatment of myelofibrosis in China [1] - Zeplin (Zepeling) is the only recombinant human thrombin developed and successfully commercialized using recombinant DNA technology in China [1]

Core Viewpoint - Rebio Biotech is undergoing a listing hearing on the Hong Kong Stock Exchange, with CICC and Citibank serving as joint sponsors. The company is a key player in the global small nucleic acid drug development field, particularly in siRNA therapies, and possesses one of the largest siRNA drug pipelines globally [1] Group 1: Market Potential - The small nucleic acid drug market is considered the "third wave" following small molecules and antibody drugs, with significant market potential. It is projected that the global market valuation will reach $18.6 billion by 2029, with a compound annual growth rate (CAGR) of 29.5% from 2024 to 2029 [1] Group 2: Technological Advancements - Rebio Biotech has overcome the core technical barrier of small nucleic acid drug delivery, possessing proprietary and clinically validated GalNAc delivery technology. The liver-targeting RiboGalSTAR delivery technology is foundational to many of its pipeline assets. The company has also made significant progress in extrahepatic delivery technologies, such as RiboPepSTAR and RiboOncoSTAR [1] Group 3: Product Pipeline - The company is deeply focused on the small nucleic acid sector, with seven self-developed drugs in clinical trials targeting eight indications related to cardiovascular, metabolic, renal, and liver diseases. Four of these drugs are in Phase 2 clinical trials. The core product RBD4059 is the world's first and fastest siRNA drug for treating thrombotic diseases. RBD5044 and RBD7022 are the second siRNA drugs globally to enter clinical development targeting APOC3 and PCSK9, respectively. Additionally, the company has over 20 preclinical projects [1]

Group 1: Company Overview - Daotong Technology has submitted a listing application to the Hong Kong Stock Exchange, with CICC as the sole sponsor [1] - The company is a global leader in smart vehicle diagnostics and intelligent charging solutions, holding the largest market share in smart vehicle diagnostics, which is projected to grow from 9.1% in 2022 to 11.1% in 2024 [1] - By 2024, Daotong is expected to be the largest provider of intelligent charging solutions in China and the fourth largest in North America based on revenue [1] - The company has over 20 years of industry experience and offers a comprehensive solution portfolio based on strong technological capabilities [1] - Daotong has established a sales network covering approximately 100 countries and regions, collaborating with over 800 global distributors and directly serving top energy companies, mainstream charging facility operators, and Fortune 500 companies [1] Group 2: Industry Insights - The importance of smart vehicle diagnostics is increasing in the context of vehicle electrification and intelligence trends [2] - The industry is addressing traditional diagnostic efficiency and accuracy issues through AI voice assistants, smart detection, and cloud collaboration [2] - The global market size for smart vehicle diagnostics is expected to grow from approximately $3.832 billion in 2024 to about $8.004 billion by 2030, with a compound annual growth rate (CAGR) of 13.1% [2] - The share of software solutions in the market is projected to increase significantly from 16.8% in 2024 to 26.7% by 2030 [2]

Core Viewpoint - Recent fluctuations in A-shares have led to divergent expectations among investors during the "cross-year" phase, but the short-term impact of internal and external factors on A-shares may be nearing its end, with a relatively loose liquidity environment expected to persist into the first quarter of next year [1] Group 1: Market Environment - The current low-interest-rate environment is likely to continue driving the trend of "deposit migration" among residents, providing a favorable opportunity for investors to position themselves for the "cross-year" market [1] - The recent pullback in indices has created a good entry point for investors looking to capitalize on upcoming market trends [1] Group 2: Investment Strategy - Investors are advised to focus on growth styles during market dips, while dividend styles should emphasize phase-specific and structural opportunities [1] - Three main investment themes are recommended: 1. **Growth in Prosperous Sectors**: The AI technology sector is expected to transition into an application phase next year, with opportunities in computing power, optical modules, and cloud computing infrastructure, particularly in domestic markets. Key application areas include robotics, consumer electronics, intelligent driving, and software applications. Additionally, innovative pharmaceuticals, energy storage, and solid-state batteries are entering a prosperous cycle [1] 2. **External Demand Breakthrough**: The trend of going overseas presents a relatively certain growth opportunity. Sectors to focus on include home appliances, construction machinery, commercial buses, power grid equipment, gaming, and globally priced resources such as non-ferrous metals [1] 3. **Cyclical Reversal**: Attention should be given to sectors nearing improvement points in supply-demand dynamics or benefiting from policy support, such as chemicals, aquaculture, and new energy [1] - Dividend sectors possess defensive attributes but may still be more phase-specific and structural in nature, suggesting a bottom-up stock selection approach based on quality free cash flow [1]

Core Viewpoint - The article discusses the recent divergence between the strengthening of the Renminbi (RMB) and the decline of the stock market, particularly in Hong Kong, raising questions about the underlying factors driving these trends [2][4][15]. Group 1: RMB Strength and Stock Market Divergence - The RMB has appreciated by 1.3% against the USD since early October, nearing the 7.0 mark, while the Hong Kong stock market has seen a significant decline, with the Hang Seng Index dropping 15% from its peak [2][4]. - Historically, a strong RMB correlates positively with stock market performance, as it typically indicates foreign capital inflow and a favorable economic outlook [2][4][6]. - The recent divergence is attributed to different driving factors for the RMB and the stock market, suggesting that the traditional correlation may not apply in the current context [4][15]. Group 2: Historical Context and Analysis - The historical relationship between the RMB and the stock market has predominantly been one of alignment, with notable exceptions occurring only twice in the past: from March to June 2013 and from July 2021 to October 2022 [9][10]. - In both historical instances, the divergence was resolved either by the stock market aligning with the RMB or vice versa, influenced by policy interventions and economic fundamentals [10][12]. - The article emphasizes that the current divergence is rare and highlights the importance of growth and capital inflow as key pricing factors for both the RMB and the stock market [7][14]. Group 3: Current Economic Conditions - The recent RMB appreciation is primarily driven by a record trade surplus of $1.08 trillion and a weakening USD, rather than significant foreign capital inflows into the stock market [15][25]. - Domestic economic indicators show a weakening trend, with PMI below the growth threshold and negative growth in fixed asset investment, suggesting that the stock market's decline reflects underlying economic pressures [22][26]. - The article posits that the RMB's strength is more a result of external factors, such as the USD's performance and seasonal capital flows, rather than improvements in domestic economic conditions [25][26]. Group 4: Future Outlook - The article suggests that the divergence between the RMB and the stock market may persist, as the factors causing this divergence are not expected to change in the short term [28][29]. - The future trajectory of both the RMB and the stock market will depend on the direction of economic fundamentals and whether policy measures can effectively address the current economic challenges [31][36]. - A significant policy response aimed at stimulating domestic demand could potentially realign the RMB and stock market trends, but without such measures, the divergence may continue [36][37].

Core Viewpoint - In 2025, China's capital market continued to recover, enhancing the securities industry's ability to serve the real economy and new productive forces, with significant improvements in investor asset allocation and satisfaction. The merger of Guotai Junan and Haitong Securities was completed, accelerating the construction of a first-class investment bank, while securities firms strengthened their overseas subsidiaries, deepening high-level opening-up. Looking ahead to 2026, the securities industry's functional capabilities are expected to be better utilized, contributing to the construction of a financial powerhouse [1]. Industry Development: Functional Capabilities and Capital Strength - The securities industry's functional capabilities became increasingly significant in 2025, serving the real economy and new productive forces effectively. Notable companies such as Moer Thread and Nidec were listed, and major firms like CATL and Zijin Mining successfully completed IPOs in Hong Kong, with the Hong Kong Stock Exchange regaining its position as the top global IPO market [2]. - Investor satisfaction improved significantly in 2025, with the scale of financial products sold by securities firms growing. In the first half of the year, 42 listed securities firms achieved financial product sales revenue of 5.568 billion yuan, a year-on-year increase of 32% [2]. Investment Banking: Recovery and Service to the Real Economy - In 2025, the investment banking sector showed signs of recovery, focusing on serving the real economy through equity financing and mergers and acquisitions. The A-share IPO market saw over 100 companies listed, with total fundraising reaching 110 billion yuan, indicating a shift towards quality over quantity [5]. - The Hong Kong IPO market also rebounded, with 91 companies completing IPOs and raising a total of 259.889 billion HKD, marking a significant recovery [6]. - Mergers and acquisitions became a key avenue for investment banks to deepen their service to the real economy, with policies guiding the market towards industry integration and transformation [6]. Wealth Management: Transition to Management Fees - In 2025, the wealth management business of securities firms saw significant growth, with total revenue from related businesses reaching approximately 145.028 billion yuan, a year-on-year increase of 37.4% [9]. - The shift from earning transaction commissions to management and service fees was evident, with online account openings exceeding 90% and over 80% of transactions conducted via mobile apps [11]. - The demand for wealth management services is expected to grow, driven by an increase in residents' financial assets, particularly in equity [12]. Asset Management: New Development Paths - The asset management industry underwent significant restructuring in 2025, with total private asset management product scale reaching 57.9 trillion yuan, an increase of 5.95% from the beginning of the year [13]. - The pursuit of public fund licenses by securities firms was paused, with many withdrawing applications, indicating a shift towards exploring differentiated development paths [14]. - Collaboration between asset management and wealth management is emerging as a new development path, with a focus on meeting diverse client needs [15]. Mergers and Acquisitions: Accelerated Restructuring - The wave of mergers and acquisitions in the securities industry intensified in 2025, with significant cases such as the merger of Guotai Junan and Haitong Securities and the absorption of Dongxing Securities and Xinda Securities by CICC [16][17]. - The restructuring is characterized by a focus on resource integration and strategic transformation, supported by clear policy incentives [17]. - The industry is expected to see a clearer new structure in 2026, with a focus on leading firms and potential growth among mid-sized securities companies [18].

Core Viewpoint - The article highlights the potential investment opportunities in the Hong Kong stock market as it approaches a year-end trading window, with favorable policy support for the consumer sector and low valuation levels in various sub-sectors [1][5][11]. Group 1: Market Insights - Hong Kong stocks are experiencing a year-end trading window, with quality assets entering a high cost-performance zone due to macroeconomic improvements and profit expectations [5]. - The Japanese central bank's recent interest rate hike to 0.75% is expected to improve overseas liquidity expectations, which may positively impact global markets [3]. - The U.S. stock market is anticipated to remain volatile, particularly high-valuation assets, as it navigates between revaluation and sentiment recovery [7]. Group 2: Sector Analysis - The consumer sector is positioned for recovery, with multiple sub-sectors currently at historically low valuation levels, benefiting from policy support aimed at enhancing corporate profitability [11]. - Strong cyclical sectors such as non-ferrous metals, aluminum, chemicals, and machinery are expected to be key trading catalysts in the first quarter of 2026 [6]. - Industrial metals are projected to maintain a long-term positive trend despite short-term price pressures due to uncertainties in interest rates and the dollar [12]. Group 3: Economic Outlook - The overall economic growth in 2026 is expected to remain under pressure, but investment may stabilize at low levels, with gradual improvements in consumption and resilient exports [10]. - The market is likely to transition from a valuation-driven rally to one supported by corporate earnings, with a focus on modernization and capacity expansion as key trends [10]. - The trust in the U.S. dollar is declining, which may influence global economic dynamics and investment strategies [15].

Core Viewpoint - The Chinese securities industry is undergoing a significant wave of integration driven by policies, with major mergers such as CICC's absorption of Dongxing Securities and Xinda Securities, aiming to create a "carrier-level" brokerage firm with total assets exceeding 1 trillion yuan [1][2]. Industry Integration Trends - The current wave of mergers is characterized by a shift from simple scale expansion to a focus on functional synergy and professional capabilities, aligning with national strategies to optimize financial supply and develop first-class investment banks [1][3]. - Notable mergers include Guotai Junan's absorption of Haitong Securities and Guosen Securities' acquisition of Wanhua Securities, reflecting diverse motivations such as creating international investment banks and enhancing competitiveness among specialized brokerages [2][4]. Policy Influence - The integration is guided by national strategies, including the "14th Five-Year Plan," which emphasizes optimizing the financial institution system and enhancing resource integration capabilities [4][5]. - Regulatory support is crucial for facilitating mergers, with expectations that future policies may allow for more flexible transactions involving licenses and customer resources [6]. Competitive Landscape - The merger of CICC with Dongxing and Xinda is expected to alter the competitive dynamics among leading brokerages, increasing pressure on other firms [2][3]. - The industry is witnessing a "Matthew Effect," where leading firms are consolidating to strengthen their market positions, while smaller firms are focusing on niche markets and specialized services [7][9]. Future Directions - Leading brokerages are encouraged to enhance their roles in serving the real economy and new productive forces, focusing on sectors like AI, biomedicine, and green energy [7][8]. - Smaller brokerages should adopt a "specialized and innovative" approach, leveraging local industry resources and focusing on areas like green finance and technology finance to build competitive advantages [8][9].

内蒙古双欣环保材料股份有限公司（以下简称"双欣环保"、"发行人"或"公司"）首次公开发行人民币普 通股（A股）（以下简称"本次发行"）并在主板上市的申请已经深圳证券交易所（以下简称"深交所"） 上市审核委员会审议通过，并已获中国证券监督管理委员会同意注册（证监许可〔2025〕2478号）。 中国国际金融股份有限公司（以下简称"中金公司"、"保荐人"、"主承销商"或"保荐人（主承销商）"） 担任本次发行的保荐人（主承销商）。 登录新浪财经APP 搜索【信披】查看更多考评等级 特别提示 本次发行采用向参与战略配售的投资者定向配售（以下简称"战略配售"）、网下向符合条件的网下投资 者询价配售（以下简称"网下发行"）和网上向持有深圳市场非限售A股股份和非限售存托凭证市值的社 会公众投资者定价发行（以下简称"网上发行"）相结合的方式进行。 发行人与保荐人（主承销商）协商确定本次发行股份数量为28,700.0000万股，发行价格为人民币6.85 元/股。 本次发行初始战略配售数量为8,610.0000万股，约占本次发行数量的30.00%。最终战略配售数量为 7,954.6567万股，占本次发行数量的27.72%。本次发行 ...